Dyadic announces first quarter 2024 financial results and highlights recent company progress

Human health sector final clinical study report has been issued for the first-in-human phase 1 clinical trial demonstrating safety and antibody response for dyai-100, a recombinant protein receptor binding domain booster vaccine candidate for protection against covid-19 infection entered into several fully funded vaccine and antibody projects covering more than twelve targets, five of which are funded by two of the top ten pharmaceutical companies successfully expressed a h1n1 influenza antigen in our collaboration with the vaccine and immunotherapy center (“vic”) at massachusetts general hospital announced strategic partnership to develop affordable rabies prophylactics and vaccines using c1-cell protein production platform published a manuscript of preclinical studies on c1 produced monoclonal antibody in non-human primates and hamsters in prestigious peer-reviewed journal nature communications advanced collaboration with israel institute for biological research (iibr) targeting bio-threats and emerging disease solutions c1 produced adjuvanted recombinant ferritin nanoparticle h5n1 “bird flu” human vaccine candidate demonstrated a strong immune response in animal studies animal health sector c1 produced adjuvanted recombinant ferritin nanoparticle h5n1 “bird flu” human vaccine candidate demonstrated a strong immune response in animal studies for potential use in poultry, cattle and other animals expanded collaboration with phibro/abic to develop vaccines and treatments for companion and livestock animal diseases alternative proteins sector executed a term sheet to utilize our microbial protein production platforms to develop production strains for the production of recombinant serum albumin advanced development of 6 product candidates for non-pharmaceutical applications utilizing the dapibus™ platform technology corporate closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrants appointed mr. patrick lucy as board chairman and mr.
DYAI Ratings Summary
DYAI Quant Ranking